ClinicalTrials.gg
RecruitingNCT05872724Updated May 24, 2023

Optimization of Postoperative Adjuvant Therapy for Cervical Cancer Based on MRD(Minimal Residual Disease)

A Phase 2 interventional study of Chemoradiotherapy + Adjuvant chemotherapy and Zimberelimab and Chemoradiotherapy (small pelvic) + Zimberelimab in Cervical Cancer, sponsored by Suzhou Municipal Hospital. Recruiting at 1 site in China. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-05-24.

Sponsored by Suzhou Municipal Hospital · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jan 2023; still recruiting 3 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
32
Allocation
Non-randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 458 studies in Uterine Cervical Neoplasms with a site in China — 208 open to participants now, 243 under way, 35 of them phase 3. Uterine Cervical Neoplasms · China.

Planned enrollment
274th of 363
32 · median 89
Started
2023
with 49 others
Phase 2
139 of 458
73 open now
Primary completion
2028-01
later than 200 of 242 live
Registered
279th of 458
by date

Among the 458 studies in Uterine Cervical Neoplasms with a site in China, this one is the 274th largest by planned enrollment of the 363 interventional ones that give a count, is one of 50 that started in 2023, is one of 139 in phase 2, reaches primary completion later than 200 of the 242 other live ones, and was the 279th registered.

Uterine Cervical Neoplasms

2,369 studies on the registry are indexed under Uterine Cervical Neoplasms; 678 are open to participants now.

Browse Uterine Cervical Neoplasms studies →

Open to participants now

208 of the 458 studies in Uterine Cervical Neoplasms with a site in China are open now. Recruiting first, the newest first:

203 more — sign in →

All 208 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 476 Uterine Cervical Neoplasms studies recruiting now, 245 (51%) set no upper age limit and 191 (40%) stop at 75 or younger; 20 take children under 18; 68 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 458 studies in Uterine Cervical Neoplasms with a site in China, or all of them as a file.
02

Study summary

This study is a prospective cohort clinical trial that aims to investigate the safety and efficacy of a combined chemoradiotherapy and immunotherapy treatment for early postoperative cervical cancer. Specifically, this study seeks to evaluate the ability of MRD-based screening to detect and monitor changes in MRD status at different stages of treatment, its potential for use in monitoring patient recurrence rates and in prognosis evaluation. In addition, this study will investigate the safety and effectiveness of chemoradiotherapy combined with immunotherapy as a postoperative adjuvant therapy for patients identified to be at risk of early cervical cancer based on MRD screening.

Read the detailed description

The study comprised of three periods; a screening period (within 28 days prior to informed consent), a treatment period (defined as the time from the initiation of treatment to its termination for any reason), and a follow-up period (consisting of end-of-treatment visits, safety visits, and survival follow-up). During the screening period, participants underwent eligibility evaluations, including tissue and blood sample collection for biomarker detection. Eligible subjects were divided into high-risk and intermediate-risk groups based on Peter's criteria and Sedlis criteria, with patients in the high-risk group or those identified as MRDc0 (+) (3 days after surgery to 10 days before adjuvant therapy) receiving conventional pelvic concurrent chemoradiotherapy, adjuvant chemotherapy, and four courses of immunotherapy. Patients in the intermediate-risk group and those identified as MRDc0 (-) received simultaneous chemoradiotherapy in the target volume of the small pelvis, four courses of immunotherapy, continued immunotherapy with MRDIn(+)(2 months after initiation of immunotherapy), and follow-up monitoring with MRDIn(-). Subjects returned to the hospital for a safety follow-up 28 days (±7d) after the last dose to track the outcome of adverse events. Safety visits consisted of vital sign measurements, laboratory tests, and other protocol-required assessments to evaluate adverse events, concomitant medications, and concomitant therapy. At the end of treatment, subjects began survival follow-up every 3 months (±7d). Radiographic assessments were conducted at this frequency until disease progression, death, loss of follow-up, withdrawal of informed consent, initiation of follow-up antitumor therapy, or investigator-initiated termination of the study.

03

Conditions studied

  • Cervical Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients with histopathological and clinical (FIGO 2018) stage ⅠB2 \~II A2 cervical cancer.
  2. Above the age of 18.
  3. General status: score 0-2.
  4. Be able to understand the research scheme, voluntarily participate in the study, and sign the .
  5. Good compliance, able to cooperate with the collection of specimens at each node and provide corresponding clinical information.

Exclusion criteria

Exclusion Criteria:

  1. Suffering from other malignant tumors.
  2. Do not receive the specified treatment or change the treatment regimen before the disease progresses.
  3. The study cannot be followed up according to the defined clinical follow-up period.
  4. Unable to accept or provide CT or other designated therapeutic evaluation means.
  5. Have an disease.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
32 participants (estimated)

Study arms

  • Experimental
    Arm A

    Eligible subjects were assigned to high-risk or medium-risk groups based on Peter's criteria and Sedlis criteria. Patients with a high-risk classification or MRDc0 (+) status received a treatment consisting of conventional pelvic concurrent chemoradiotherapy, adjuvant chemotherapy, four courses of immunotherapy, continued immunotherapy with MRDIn(+), and follow-up monitoring with MRDIn(-)

    Drug: Chemoradiotherapy + Adjuvant chemotherapy and Zimberelimab

  • Experimental
    Arm B

    Patients deemed intermediate risk and with MRDc0 (-) status received concurrent chemoradiotherapy in the small pelvic target volume, four courses of immunotherapy, continued immunotherapy with MRDIn(+), and follow-up monitoring with MRDIn(-)

    Drug: Chemoradiotherapy (small pelvic) + Zimberelimab

Interventions

  • DrugChemoradiotherapy + Adjuvant chemotherapy and Zimberelimab

    Drug page: ZimberelimabStudies of ZimberelimabZimberelimab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    * Radiation therapy: 1. Irradiation mode and dose: 6MV-X-ray (6Megavoltage-X-ray), IMRT or RapidArc-IMRT were used for external radiotherapy. External radiotherapy dose: PTV (Planning Target Volume) 45-50Gy/25 times. * Chemotherapy: 1. Concurrent chemotherapy: Cisplatin monotherapy: DDP 75 mg/m2 for 3 days, q3w. Carboplatin or nedaplatin may be used in patients that cannot tolerate cisplatin. 2. Adjuvant chemotherapy: After the concurrent chemoradiotherapy, 4 cycles of consolidation chemotherapy plus immunotherapy are recommended for patients with high risk or MRDc0 (+). Recommended chemotherapy regimen: liposome paclitaxel 135mg/m2 d1 +DDP 25 mg/m2 D1-3, Q21. * Zimberelimab injection: 240 mg, IV, q3w. Start the drug one day before the start of postoperative radiotherapy.

  • DrugChemoradiotherapy (small pelvic) + Zimberelimab

    Drug page: ZimberelimabStudies of ZimberelimabZimberelimab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Radiation therapy: 1. Target volume of radiotherapy for small pelvis: CTVp includes tumor bed area, paracentral area and part of vagina; CTVn includes bilateral internal iliac, external iliac and obturator lymphatic drainage areas. Upper boundary to sacroiliac joint level, lower boundary to 2cm below vaginal stump. Chemotherapy: Concurrent chemotherapy: Cisplatin monotherapy: DDP 75 mg/m2 for 3 days, q3w. Carboplatin or nedaplatin may be used in patients that cannot tolerate cisplatin. Adjuvant chemotherapy: After the concurrent chemoradiotherapy, 4 cycles of adjuvant immunotherapy are recommended for patients in good general condition (ECOG: 0-1) with medium risk and MRDc0 (-). Zimberelimab injection: 240 mg, IV, q3w. Start the drug one day before the start of posterior radiotherapy.

06

What researchers measure

Primary outcomes

  1. 3-year DFS in ITT population (intent-to-treat population)

    DFS (disease-free survival) is the time between the start of enrollment and the recurrence of disease, or death from any cause.

    Time frame: 3-year

Secondary outcomes

  1. 3-year DFS with different MRD status and changes

    DFS (disease-free survival) is the time between the start of enrollment and the recurrence of disease, or death from any cause

    Time frame: 3-year

  2. 2-year DFS with different MRD status and changes

    DFS (disease-free survival) is the time between the start of enrollment and the recurrence of disease, or death from any cause

    Time frame: 2-year

  3. 1-year DFS with different MRD status and changes

    DFS (disease-free survival) is the time between the start of enrollment and the recurrence of disease, or death from any cause

    Time frame: 1-year

  4. 3-year OS rates in patients with different MRD status and changes

    OS (overall survival) is the overall time from enrollment to death from any cause

    Time frame: 3-year

  5. AE

    Adverse events (AE) were determined and graded according to NCI CTC AE 5.0, Collect the incidence of adverse events (AEs), the incidence of serious adverse events (SAEs), the incidence of CTCAE grade 3 or above (rated based on CTCAE 5.0), the correlation of adverse events, actions taken and outcomes, etc.

    Time frame: Up to 28 days after the end of treatment

Other outcomes

  1. Disease recurrence based on MRD monitoring methods

    The time from MRD(-) to MRD(+)

    Time frame: through study completion, an average of 3-6 months

  2. Negative conversion rate of MRD (+) patients after intensive adjuvant therapy

    Incidence of conversion from MRD(+) to MRD(-) after adjuvant therapy

    Time frame: through study completion, an average of 3-6 months

  3. To explore the correlations of genes detected by next-generation sequencing, MRI-based response patterns and biomarkers of peripheral blood with the efficacy of treatment.

    Time frame: 3-year

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — CRF (Case Report Form) and ICF (Informed Consent Form) will be shared in the future

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2023 (actual). Primary completion is estimated for Jan 2028, 60 months after the start.

Of 155 non-industry phase 2 interventional studies under Uterine Cervical Neoplasms, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 88. This study's planned 60 months is above that.

Counting every sponsor, half of 205 studies reached it within 42 months; a quarter within 29 and three quarters within 70.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 12, 2023
First posted
May 24, 2023
StartActual
Jan 16, 2023
Primary completionEst.
Jan 16, 2028
CompletionEst.
Dec 30, 2028
Last update
May 24, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 24, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05872724
Lead sponsor
Suzhou Municipal Hospital
Responsible party
jing xue (Associate chief physician, Suzhou Municipal Hospital) — Principal investigator
First posted
May 24, 2023
Start date
Jan 16, 2023
Primary completion
Jan 16, 2028 (estimated)
Completion
Dec 30, 2028 (estimated)
Last update
May 24, 2023

Study contacts

jing xue
Contact
jxue@njmu.edu.cn
(+86)13771734347
jing xue
principal investigator · The Affiliated Suzhou Hospital of Nanjing Medical University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zimberelimab

Start the discussion